2910-75-0

Basic information

• Product Name: 1-(4-hydroxy-3-methylphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one
• Synonyms: 1-(4-hydroxy-3-methylphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one
• CAS NO: 2910-75-0
• Molecular Weight: 254.285
• Mol File: 2910-75-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-(4-hydroxy-3-methylphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-hydroxy-3-methylphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one(2910-75-0)
• EPA Substance Registry System: 1-(4-hydroxy-3-methylphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one(2910-75-0)

Safety Data

• Hazardous Substances Data: 2910-75-0(Hazardous Substances Data)

Upstream product

• 876-02-8 4-hydroxy-3-methylphenyl methyl ketone 
• 123-08-0 4-hydroxy-benzaldehyde 

Relevant articles and documents

In vitro and in vivo synergistic interaction of substituted chalcone derivatives with norfloxacin against methicillin resistant Staphylococcus aureus

Thirty chalcone derivatives were synthesized via a base catalyzed Claisen Schmidt condensation and evaluated for their anti-methicillin-resistant Staphylococcus aureus (MRSA) activity alone and in combination with norfloxacin. Among these, 5 derivatives namely trans-3-(1H-indol-3-yl)-1-(4′-benzyloxyphenyl)-2-propen-1-one (2), 1-(4″-biphenyl)-3-(3′4′-dihydroxyphenyl)-2-propen-1-one (11), 1-(4″-hydroxy-3″-methylphenyl)3-(4′-hydroxyphenyl)-2-propen-1-one (14), 3-(4′-chlorophenyl)-1-(4″-hydroxyphenyl)2-propen-1-one (17), and LTG-oxime (27) showed significant antibacterial activity with MIC 12.5-50 g mL-1 respectively. In combination studies, derivatives 2 and 14 significantly reduced the MIC of norfloxacin by up to 16 fold (FICI 0.5), while derivatives 11, 17 and 27 reduced it by up to eight fold (FICI ≤ 0.5). Flow cytometry analysis results clearly indicated that derivatives 2 and 14 significantly promote the accumulation and inhibition of the Et-Br efflux, which was further validated through spectrofluorimeter using clinical isolate MRSA-ST2071. In systemically infected Swiss albino mice model, both the compounds significantly (P 0.001, P 0.01) lowered the systemic bacterial load in blood, liver, kidney, lung and spleen tissues. This study supports the promising use of chalcones in the development of economical antibacterial combinations.